12526
document
Single-dose tranexamic acid reduces postoperative bleeding after coronary surgery in patients treated with aspirin until surgery . UNLABELLED Tranexamic acid reduces postoperative bleeding after coronary artery bypass grafting . We evaluated the effects of a single dose of tranexamic acid given immediately before cardiopulmonary bypass ( CPB ) in patients treated with aspirin until the day before surgery . The study was a prospective , randomized , double-blinded , placebo-controlled , parallel-group trial . Eighty patients were included and divided into two groups : one group received tranexamic acid 30 mg/kg , and one group received placebo ( 0.9 % NaCl ) as a bolus injection before CPB . Postoperative blood loss was recorded for 16 h. Transfusions of blood products were recorded for the whole hospital stay . Transfusions of packed red cells were given when the hematocrit value was less than 20 % during CPB and less than 25 % after surgery . The patients in the tranexamic acid group had significantly less postoperative bleeding compared with the patients in the placebo group ( mean [ SD ] ) ( 475 [ 274 ] mL versus 713 [ 243 ] mL ; P < 0.001 ) . An effective inhibition of fibrinolysis was found in patients receiving tranexamic acid . Tranexamic acid reduces postoperative bleeding in coronary artery bypass grafting patients treated with aspirin until the day before surgery . IMPLICATIONS Continuation of aspirin medication until the day before coronary artery bypass grafting may increase postoperative bleeding . The administration of a single dose of tranexamic acid ( 30 mg/kg ) immediately before cardiopulmonary bypass significantly reduced postoperative bleeding and inhibited fibrinolysis in these patients .
12527
Intervention_Pharmacological
tranexamic acid
12528
Intervention_Surgical
coronary surgery
12529
Intervention_Pharmacological
aspirin
12530
Intervention_Pharmacological
Tranexamic acid
12531
Intervention_Surgical
coronary artery bypass grafting
12532
Intervention_Pharmacological
tranexamic acid
12533
Intervention_Surgical
cardiopulmonary bypass ( CPB )
12534
Intervention_Pharmacological
aspirin
12535
Intervention_Control
placebo-controlled
12536
Intervention_Pharmacological
tranexamic acid 30 mg/kg ,
12537
Intervention_Control
placebo
12538
Intervention_Pharmacological
Transfusions
12539
Intervention_Pharmacological
tranexamic acid
12540
Intervention_Control
placebo
12541
Intervention_Pharmacological
tranexamic acid . Tranexamic acid
12542
Intervention_Surgical
coronary artery bypass grafting
12543
Intervention_Pharmacological
aspirin
12544
Intervention_Surgical
coronary artery bypass grafting
12545
Intervention_Pharmacological
tranexamic acid
12546
Outcome_Physical
postoperative bleeding
12547
Outcome_Physical
effects
12548
Outcome_Physical
Postoperative blood loss
12549
Outcome_Physical
Transfusions of blood products
12550
Outcome_Physical
hematocrit value
12551
Outcome_Physical
postoperative bleeding
12552
Outcome_Physical
inhibition of fibrinolysis
12553
Outcome_Physical
postoperative bleeding
12554
Outcome_Physical
postoperative bleeding .
12555
Outcome_Physical
postoperative bleeding
12556
Outcome_Physical
fibrinolysis
12557
Participant_Condition
surgery
12558
Participant_Condition
surgery
12559
Participant_Sample-size
Eighty patients
12560
Participant_Sample-size
The patients in the tranexamic acid group
12561
Participant_Sample-size
the patients in the placebo group